Puma demonstrated strong Q4 2025 commercial momentum with total revenue of $75.5M and product revenue of $59.9M, guiding 2026 net NERLYNX product revenue of $194M–$198M. The company is developing alisertib, a small molecule inhibitor of aurora kinase A for multiple cancer indications including breast cancer, small cell lung cancer, and head and neck cancer.
Cyborg Score Rationale
Puma achieved strong profitability metrics with a 36.17% return on equity and 17.45% net margin in Q4 2025. The company guides full-year 2026 GAAP net income of $10M–$13M despite expecting a small Q1 net loss, demonstrating pathway to sustained profitability. However, higher R&D spending (30-35% increase) and liquidity of ~$97.5M with ~$22M debt could strain cash if commercial trends weaken.
Top Insights
Puma targets $194–$198M in 2026 NERLYNX revenue with alisertib trials in breast and lung cancer progressing, including interim data expected in Q2 2026.
75% of new NERLYNX patients started on reduced dose in Q4 2025 as the company implements dose escalation strategy to mitigate diarrhea side effects.
Management is strategically staggering clinical trials to maintain profitability and plans to become debt-free with only 2 remaining debt payments.
Expected higher gross-to-net reductions (27.5–28.5% for full-year 2026; 29.5–30.5% in Q1 2026) may pressure near-term margins and results.
Named Competitors
Herceptin / Perjeta — HER2-targeted monoclonal antibodies for breast cancer
Tykerb — Dual HER1/HER2 inhibitor for breast cancer
Enhertu — HER2-directed antibody-drug conjugate for breast cancer
Recent Developments
(February 2026) Puma presented at TD Cowen's 46th Annual Health Care Conference outlining 2026 guidance of $214M–$221M total revenue.
(February 2026) Q4 2025 earnings beat estimates with $0.26 EPS vs. $0.24 consensus and $75.5M revenue vs. $68.6M estimate.
(Q2 2026 Expected) Interim data presentation from ALISCA-Breast1 Phase II trial of alisertib in metastatic breast cancer.
Open the full interactive Puma Biotechnology, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.